No Data
No Data
Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights
Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity and best-in-class
Medicenna Announces EMA Approval of Its Clinical Trial Application to Expand Its Phase 1/2 ABILITY-1 Study to Europe
- ABILITY-1 study is currently enrolling patients for the treatment of advanced solid tumors with MDNA11, a novel long-acting IL-2 super-agonist, as a monotherapy or in combination with KEYTRUDA, at clinical trial
Medicenna Reports Significant Survival Benefit in Patients With Recurrent Glioblastoma Following Treatment With Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting
Single treatment with bizaxofusp achieved significant survival benefit (mOS of 13.5 vs. 7.2 months, p=0.009) and reduced risk of death by almost half (hazard ratio: 0.54, 95% confidence interval: 0.34-0.83) versus a
Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response With MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum
MDNA11 demonstrates durable response in pancreatic cancer patient with 100% regression of target and non-target lesions for over 104 weeks and continues to show remission 4 months after stopping treatment Melanoma
Medicenna to Present Clinical Update on MDNA11 ABILITY-1 Trial at Sachs Oncology Innovation Forum
Medicenna Therapeutics (MDNA.TO), whose shares rose 4.4% yesterday, on Wednesday said it will present an update on the MDNA11 ABILITY-1 Trial at the 10th annual Sachs Oncology Innovation Forum on May
Medicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program Committee
Medicenna Therapeutics (MDNA.TO) said the American Society of Clinical Oncology (ASCO) has withdrawn its abstract detailing results from the ABILITY-1 monotherapy dose escalation study with MDNA11, in
No Data
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.
Rana Hasan1 : List too long